NASDAQ:TNXP Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis $8.07 -0.84 (-9.43%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$8.11 +0.04 (+0.50%) As of 10/5/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Tonix Pharmaceuticals Stock (NASDAQ:TNXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tonix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$8.00▼$8.8250-Day Range$8.07▼$14.1052-Week Range$8.00▼$24.67Volume1.14 million shsAverage Volume445,085 shsMarket Capitalization$138.40 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingBuy Company Overview Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing medicines and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company combines small-molecule drugs, biologics, and vaccine platforms in its research and development programs. Tonix’s pipeline has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for the management of fibromyalgia and other pain-related conditions. The company has also pursued therapies based on intranasal oxytocin for conditions such as obesity and neurodevelopmental disorders, as well as vaccine candidates intended to address diseases including smallpox, mpox, and COVID-19. Tonix Pharmaceuticals was founded in 2007 and is headquartered in Chatham, New Jersey. The company’s programs are primarily developed through research, clinical testing, and collaborations, with potential applications in the United States and international markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.AI Generated. May Contain Errors. Read More Tonix Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreTNXP MarketRank™: Tonix Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 86th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingTonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTonix Pharmaceuticals has a consensus price target of $24.50, representing about 203.6% upside from its current price of $8.07.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Tonix Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($9.90) to ($6.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tonix Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.89% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 8.14.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently decreased by 8.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.30 News SentimentTonix Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 11 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows6 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Tonix Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $40,180.00 in company stock, which represents 0.0290% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,180.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.00% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by Institutions82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tonix Pharmaceuticals' insider trading history. Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNXP Stock News HeadlinesTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenOctober 4 at 1:07 AM | americanbankingnews.comTonix Pharmaceuticals Holding Corp (TNXP)September 23, 2026 | in.investing.comMAJOR BUY ALERT: Elon, Data Centers, SpaceStock picker Luke Lango recently toured Vegas and counted more than 60 new data centers under construction, evidence of what he calls a 127 trillion dollar trend reshaping global power. The convergence involves Elon Musk, China, AI, robotics, and an energy breakthrough one Berkeley and Harvard trained physicist calls the greatest transition in history. Lango has previously flagged AMD, Palantir, and Tesla before major moves and says this new trend could be his biggest find yet. | InvestorPlace (Ad)Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®September 22, 2026 | finance.yahoo.comTonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®September 22, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)September 16, 2026 | theglobeandmail.comTonix Pharmaceuticals Holding Corp. (TNXP)September 15, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Tyra Bioscience (TYRA) and Becton Dickinson (BDX)September 9, 2026 | theglobeandmail.comSee More Headlines TNXP Stock Analysis - Frequently Asked Questions How have TNXP shares performed this year? Tonix Pharmaceuticals' stock was trading at $15.62 on January 1st, 2026. Since then, TNXP stock has decreased by 48.3% and is now trading at $8.07. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings results on Monday, August, 10th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.20. The business had revenue of $13.54 million for the quarter, compared to the consensus estimate of $7.72 million. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative trailing twelve-month return on equity of 68.99%. Read the conference call transcript. When did Tonix Pharmaceuticals' stock split? Tonix Pharmaceuticals's stock reverse split on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Company Calendar Last Earnings8/10/2026Today10/05/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TNXP's financial health is in the Yellow zone, according to TradeSmith. TNXP has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TNXP CIK1430306 Webwww.tonixpharma.com Phone(862) 799-8599Fax212-923-5700Employees142Year Founded2007Price Target and Rating Average Price Target for Tonix Pharmaceuticals$24.50 High Price Target$27.00 Low Price Target$22.00 Potential Upside/Downside+203.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($12.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.02 million Net Margins-548.64% Pretax Margin-548.64% Return on Equity-68.99% Return on Assets-61.31% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.46 Sales & Book Value Annual Sales$13.11 million Price / Sales10.56 Cash FlowN/A Price / Cash FlowN/A Book Value$19.17 per share Price / Book0.42Miscellaneous Outstanding Shares17,150,000Free Float16,808,000Market Cap$138.40 million OptionableNot Optionable Beta1.78 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TNXP) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMAJOR BUY ALERT: Elon, Data Centers, SpaceStock picker Luke Lango recently toured Vegas and counted more than 60 new data centers under construction, ev...InvestorPlace | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
